Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDX-1342 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Patients will receive active MDX-1342. |
| Name | Type | Description |
|---|---|---|
| MDX-1342 | BIOLOGICAL | MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose. |
Inclusion Criteria: * relapsed/refractory CD19-positive CLL * At least 28 days since prior treatment for CLL * ECOG PS 0-2 * Screening laboratory values must be met Exclusion Criteria: * No prior anti-CD19 antibody tx * No active, uncontrolled infection * No prior allogeneic bone marrow transplan...
MDX-1342 is an investigational monoclonal antibody being studied for rheumatoid arthritis and chronic lymphocytic leukemia. It is in Phase 1 clinical development and is not approved by the FDA. The drug is being developed by Bristol-Myers Squibb Company.
MDX-1342 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. It is being investigated for its potential role in treating rheumatoid arthritis and chronic lymphocytic leukemia.
MDX-1342 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with rheumatoid arthritis and chronic lymphocytic leukemia.
MDX-1342 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials are ongoing to assess its safety and potential efficacy in treating rheumatoid arthritis and chronic lymphocytic leukemia.
MDX-1342 has been studied in two completed Phase 1 trials. NCT00593944 evaluated the drug in 15 patients with chronic lymphocytic leukemia in the United States. NCT00639834 studied MDX-1342 in combination with methotrexate in 26 patients with rheumatoid arthritis across multiple countries.
No alternative names for MDX-1342 have been disclosed. The drug is identified solely by its code name MDX-1342 in clinical trial registries and is being developed by Bristol-Myers Squibb Company.